CORMEDIX INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CORMEDIX INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $235.00K, a 79.07% decline year-over-year.
- CORMEDIX INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.18M, a 236.86% increase year-over-year.
- CORMEDIX INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $3.59M, a 38.37% decline year-over-year.
- CORMEDIX INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.32M, a 22.55% decline year-over-year.
- CORMEDIX INC. stock issued during period, value, stock options exercised for fiscal 2025 was $6.39M, a 17.28% decline from fiscal 2024.
- CORMEDIX INC. stock issued during period, value, stock options exercised for fiscal 2024 was $7.72M, a 2584.39% increase from fiscal 2023.
- CORMEDIX INC. stock issued during period, value, stock options exercised for fiscal 2023 was $287.74K.
- CORMEDIX INC. stock issued during period, value, stock options exercised for fiscal 2021 was $137.03K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $235.00K 10-Q · filed 2026-08-13 | $6.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.18M 10-Q · filed 2026-05-14 | $7.22M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.39M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.32M 10-Q · filed 2025-11-12 | $8.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.12M 10-Q · filed 2026-08-13 | $9.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $350.00K 10-Q · filed 2026-05-14 | $8.07M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $7.72M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.71M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $186.48K 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $33.75K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $287.74K 10-K · filed 2025-03-25 |
| 2023-09-30 | $20.13K 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $233.86K 10-Q · filed 2024-08-14 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $137.03K 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2021-06-30 | $137.03K 10-Q · filed 2022-08-11 | |
| 2019-12-31 | $5.17K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $122.70K 10-K · filed 2021-03-30 |
| 2019-09-30 | $4.76K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | |
| 2019-03-31 | $112.77K 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $11.60K 10-K · filed 2020-03-16 | |
| 2017-12-31 | $6.80K 10-K · filed 2019-05-29 | |
| 2014-03-31 | $213.65K 10-Q · filed 2014-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |